Daprodustat: First Approval
Daprodustat: First Approval
复制标题
DOI：
10.1007/s40265-020-01384-y
复制
发表时间：
2020-09-03
期刊：
影响因子：
11.5
通讯作者：
Dhillon, Sohita
中科院分区：
文献类型：
--
作者：
Dhillon, Sohita
达Produstat(DUVROQ)是葛兰素史克公司开发的用于治疗慢性肾脏疾病(CKD)患者贫血的低氧诱导因子Pro羟基酶(PHD)的小分子抑制剂。抑制PHD可阻止低氧诱导因子(HIF)的降解，导致红细胞生成素的产生，并随后诱导红细胞生成。今年6月，达Produstat在日本获得了治疗肾性贫血的第一次批准。达Produstat的临床研究正在全球多个国家进行。这篇文章总结了达Produstat开发过程中的里程碑，从而导致了第一次被批准用于治疗肾性贫血。
Daprodustat (DUVROQ) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease (CKD). Inhibition of PHD prevents degradation of hypoxia-inducible factor (HIF), leading to the production of erythropoietin and subsequent induction of erythropoiesis. In June, daprodustat received its first approval in Japan for the treatment of renal anaemia. Clinical studies of daprodustat are underway in multiple countries worldwide. This article summarizes the milestones in the development of daprodustat leading to this first approval for the treatment of renal anaemia.